Condition: COVID-19 Infection in Hematological Malignancies Patients · Sponsor: Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
The overall purpose of this project is to better understand the epidemiology of COVID-19 in patients with hematological malignancies (including hematopoietic stem cell transplant recipients) in the different European Countries. The results obtained will allow us to better know the prevalence of this complication in the different categories of patients with hematological malignancies (HMs). In order to attain the objectives previously described we will develop a multicentre, international, observational, retrospective and prospective study of consecutive cases of COVID-19 among HMs. There will be a clinical follow-up of the patients included in this study to observe the survival rate. Data collected form this study will be evaluated with a descriptive analysis.
This description comes directly from the study's public registry record.
livio pagano, Prof · +390630154180 · livio.pagano@unicatt.it
Jon Salmanton Garcia, Dr · jon.salmanton-garcia@uk-koeln.de
Always discuss trial participation with your own doctor first.
| ASST-Spedali Civili | Brescia, Italy | Recruiting |
| AOU Policlinico Federico II | Naples, Italy | Recruiting |
| Fondazione Policlinico A. Gemelli IRCCS | Rome, Italy | Recruiting |
| Istituto Nazionale Tumori Regina Elena IFO | Rome, Italy | Recruiting |
| Osp. di Circolo-Fondazione Macchi | Varese, Italy | Recruiting |
| AOUI Verona | Verona, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04733729